JP2019521989A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521989A5 JP2019521989A5 JP2018565844A JP2018565844A JP2019521989A5 JP 2019521989 A5 JP2019521989 A5 JP 2019521989A5 JP 2018565844 A JP2018565844 A JP 2018565844A JP 2018565844 A JP2018565844 A JP 2018565844A JP 2019521989 A5 JP2019521989 A5 JP 2019521989A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- composition
- use according
- administration
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 58
- 239000000203 mixture Substances 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 239000000725 suspension Substances 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 229960000397 bevacizumab Drugs 0.000 claims description 10
- 229960003876 ranibizumab Drugs 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 9
- 201000011190 diabetic macular edema Diseases 0.000 claims description 9
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 8
- 208000002780 macular degeneration Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- 101710197658 Capsid protein VP1 Proteins 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 239000012984 antibiotic solution Substances 0.000 claims description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 3
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 208000001344 Macular Edema Diseases 0.000 claims description 3
- 206010025415 Macular oedema Diseases 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920002675 Polyoxyl Polymers 0.000 claims description 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 3
- 150000001298 alcohols Polymers 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 201000010230 macular retinal edema Diseases 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229940066429 octoxynol Drugs 0.000 claims description 3
- 229920002113 octoxynol Polymers 0.000 claims description 3
- 229920001983 poloxamer Polymers 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 229950008882 polysorbate Drugs 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 238000011282 treatment Methods 0.000 claims description 3
- 238000010792 warming Methods 0.000 claims description 3
- 241000288906 Primates Species 0.000 claims description 2
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 claims description 2
- 229960002028 atropine sulfate Drugs 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 238000009827 uniform distribution Methods 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000013646 rAAV2 vector Substances 0.000 claims 2
- -1 Brij Polymers 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
- 239000007971 pharmaceutical suspension Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021197648A JP7384447B2 (ja) | 2016-06-16 | 2021-12-06 | 眼性新血管形成を低減するための組成物および方法 |
| JP2023173614A JP7606245B2 (ja) | 2016-06-16 | 2023-10-05 | 眼性新血管形成を低減するための組成物および方法 |
| JP2024213242A JP2025038012A (ja) | 2016-06-16 | 2024-12-06 | 眼性新血管形成を低減するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351231P | 2016-06-16 | 2016-06-16 | |
| US62/351,231 | 2016-06-16 | ||
| PCT/US2017/038012 WO2017218981A2 (en) | 2016-06-16 | 2017-06-16 | Compositions and methods for reducing ocular neovascularization |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021197648A Division JP7384447B2 (ja) | 2016-06-16 | 2021-12-06 | 眼性新血管形成を低減するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521989A JP2019521989A (ja) | 2019-08-08 |
| JP2019521989A5 true JP2019521989A5 (cg-RX-API-DMAC7.html) | 2020-05-28 |
| JP6990667B2 JP6990667B2 (ja) | 2022-02-03 |
Family
ID=60664289
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565844A Active JP6990667B2 (ja) | 2016-06-16 | 2017-06-16 | 眼性新血管形成を低減するための組成物および方法 |
| JP2021197648A Active JP7384447B2 (ja) | 2016-06-16 | 2021-12-06 | 眼性新血管形成を低減するための組成物および方法 |
| JP2023173614A Active JP7606245B2 (ja) | 2016-06-16 | 2023-10-05 | 眼性新血管形成を低減するための組成物および方法 |
| JP2024213242A Pending JP2025038012A (ja) | 2016-06-16 | 2024-12-06 | 眼性新血管形成を低減するための組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021197648A Active JP7384447B2 (ja) | 2016-06-16 | 2021-12-06 | 眼性新血管形成を低減するための組成物および方法 |
| JP2023173614A Active JP7606245B2 (ja) | 2016-06-16 | 2023-10-05 | 眼性新血管形成を低減するための組成物および方法 |
| JP2024213242A Pending JP2025038012A (ja) | 2016-06-16 | 2024-12-06 | 眼性新血管形成を低減するための組成物および方法 |
Country Status (19)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201810150UA (en) | 2014-03-17 | 2018-12-28 | Adverum Biotechnologies Inc | Compositions and methods for enhanced gene expression in cone cells |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| MY187898A (en) | 2015-03-02 | 2021-10-27 | Adverum Biotechnologies Inc | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| EP3528785A4 (en) | 2016-10-19 | 2020-12-02 | Adverum Biotechnologies, Inc. | MODIFIED AAV CASPIDS AND USES THEREOF |
| US11773406B2 (en) | 2017-03-17 | 2023-10-03 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression |
| MX2020006435A (es) | 2017-12-19 | 2021-02-09 | Akouos Inc | Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno. |
| WO2019169341A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| EP3789489A4 (en) * | 2018-03-30 | 2022-01-05 | Tomoki Todo | ANTI-SWEEPER TYPE ONCOLYTIC VIRUS |
| CA3137284A1 (en) * | 2019-04-24 | 2020-10-29 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| US20220332792A1 (en) * | 2019-09-04 | 2022-10-20 | University Of Massachusetts | Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof |
| JP2023509263A (ja) * | 2019-09-11 | 2023-03-08 | アドヴェラム バイオテクノロジーズ， インコーポレイテッド | アフリベルセプトをコードするａａｖ２バリアントを使用する眼内血管新生疾患を処置する方法 |
| WO2021050094A1 (en) * | 2019-09-11 | 2021-03-18 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| EP4041292A1 (en) * | 2019-10-07 | 2022-08-17 | RegenxBio Inc. | Adeno-associated virus vector pharmaceutical composition and methods |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| US20230057380A1 (en) * | 2019-11-26 | 2023-02-23 | University Of Massachusetts | Recombinant adeno-associated virus for delivery of kh902 (conbercept) and uses thereof |
| EP4103725A4 (en) * | 2020-02-14 | 2024-03-27 | Asklepios Biopharmaceutical, Inc. | METHOD FOR TREATING GENE THERAPY-ASSOCIATED TOXICITY WITH ANTIBIOTICS |
| CA3197936A1 (en) | 2020-12-01 | 2022-06-09 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| CN115869425B (zh) * | 2022-12-12 | 2024-08-20 | 北京生物制品研究所有限责任公司 | 一种aav眼用注射液及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3734262B2 (ja) | 1993-03-25 | 2006-01-11 | メルク エンド カンパニー インコーポレーテッド | 血管内皮細胞増殖因子阻害剤 |
| EP2346532B1 (en) * | 2008-10-07 | 2020-10-07 | Bracco Suisse SA | Targeting construct comprising anti-polymer antibody and microvesicles binding to the same |
| US8663624B2 (en) * | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| ES2638342T3 (es) * | 2011-04-22 | 2017-10-19 | The Regents Of The University Of California | Viriones de virus adenoasociado con cápside variante y métodos para su uso |
| TWI775096B (zh) | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| SG10201810150UA (en) * | 2014-03-17 | 2018-12-28 | Adverum Biotechnologies Inc | Compositions and methods for enhanced gene expression in cone cells |
| EP3570895A1 (en) * | 2017-01-17 | 2019-11-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of expressing a polynucleotide of interest in the cone photoreceptors |
-
2017
- 2017-06-16 RS RS20220484A patent/RS63282B1/sr unknown
- 2017-06-16 EP EP24184081.8A patent/EP4427808A3/en active Pending
- 2017-06-16 KR KR1020227041433A patent/KR102622823B1/ko active Active
- 2017-06-16 WO PCT/US2017/038012 patent/WO2017218981A2/en not_active Ceased
- 2017-06-16 EP EP22154859.7A patent/EP4083203B1/en active Active
- 2017-06-16 SG SG11201811230RA patent/SG11201811230RA/en unknown
- 2017-06-16 CA CA3027740A patent/CA3027740A1/en active Pending
- 2017-06-16 PT PT178142287T patent/PT3472317T/pt unknown
- 2017-06-16 SI SI201731153T patent/SI3472317T1/sl unknown
- 2017-06-16 AU AU2017286680A patent/AU2017286680B2/en active Active
- 2017-06-16 ES ES22154859T patent/ES2987337T3/es active Active
- 2017-06-16 EP EP17814228.7A patent/EP3472317B1/en active Active
- 2017-06-16 PL PL17814228.7T patent/PL3472317T3/pl unknown
- 2017-06-16 SM SM20220251T patent/SMT202200251T1/it unknown
- 2017-06-16 JP JP2018565844A patent/JP6990667B2/ja active Active
- 2017-06-16 HR HRP20220612TT patent/HRP20220612T1/hr unknown
- 2017-06-16 ES ES17814228T patent/ES2916344T3/es active Active
- 2017-06-16 LT LTEPPCT/US2017/038012T patent/LT3472317T/lt unknown
- 2017-06-16 DK DK17814228.7T patent/DK3472317T3/da active
- 2017-06-16 HU HUE17814228A patent/HUE059424T2/hu unknown
- 2017-06-16 EP EP25208689.7A patent/EP4674483A2/en active Pending
- 2017-06-16 KR KR1020197001022A patent/KR20190038536A/ko not_active Abandoned
-
2018
- 2018-12-12 US US16/218,350 patent/US20190100582A1/en not_active Abandoned
-
2021
- 2021-12-06 JP JP2021197648A patent/JP7384447B2/ja active Active
-
2022
- 2022-05-12 CY CY20221100331T patent/CY1125152T1/el unknown
- 2022-10-12 US US18/046,112 patent/US20230322911A1/en active Pending
-
2023
- 2023-04-13 AU AU2023202277A patent/AU2023202277A1/en active Pending
- 2023-10-05 JP JP2023173614A patent/JP7606245B2/ja active Active
-
2024
- 2024-12-06 JP JP2024213242A patent/JP2025038012A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521989A5 (cg-RX-API-DMAC7.html) | ||
| JP2019521990A5 (cg-RX-API-DMAC7.html) | ||
| JP7111924B2 (ja) | 滲出型加齢性黄斑変性の治療のための組成物 | |
| AU2021225178B2 (en) | Treatment of AMD using AAV2 variant with aflibercept | |
| HRP20220612T1 (hr) | Sastavi i metode za smanjenje očne neovaskularizacije | |
| JP2024016207A (ja) | 滲出型加齢性黄斑変性の治療のための組成物 | |
| JP2021503914A5 (cg-RX-API-DMAC7.html) | ||
| JP2018517773A (ja) | ＩｇＧＦｃドメインを有する融合タンパク質の安定な液状製剤 | |
| WO2016073918A1 (en) | Methods for treating ocular diseases | |
| MX383971B (es) | Composición farmacéutica para la prevención y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteína de fusión en la cual el péptido que penetra el tejido y la preparación del factor de crecimiento endotelial antivascular se fusionan. | |
| US20200297869A1 (en) | Sequential intravitreal administration of aav gene therapy to contralateral eyes | |
| US20130004486A1 (en) | Treatment of vascularized pigment epithelial detachment with anti-vegf therapy | |
| WO2023236964A1 (zh) | 腺相关病毒药物组合物及其用途 | |
| Zeng et al. | “Para-retinal” vector administration into the deep vitreous enhances retinal transgene expression | |
| TW202508610A (zh) | 醫藥組成物及其用途 | |
| JPWO2020180951A5 (cg-RX-API-DMAC7.html) | ||
| CN116710137A (zh) | 用于在治疗眼部疾病的方法中使用的vegf拮抗剂 | |
| Sundlisæter et al. | Antiangiogenic treatment of ocular diseases | |
| JPWO2021041373A5 (cg-RX-API-DMAC7.html) | ||
| Mellen et al. | Gene therapy for neovascular macular degeneration, diabetic retinopathy, and diabetic macular edema | |
| NZ749897A (en) | Treatment of amd using aav2 variant with aflibercept | |
| NZ749897B2 (en) | Treatment of amd using aav2 variant with aflibercept | |
| CN117535299A (zh) | 分离的核酸分子、重组病毒或其应用 | |
| Fenner et al. | When to change course: timing of treatment change in the management of diabetic macular edema | |
| Schwartz et al. | Progressive release of vitreomacular traction with aflibercept |